Evgen Pharma PLC
LSE:EVG
Evgen Pharma PLC
LSE:EVG
Price:
0.8
GBX
Market Closed
Market Cap:
£3.4m
Balance Sheet
Balance Sheet Decomposition
Evgen Pharma PLC
Evgen Pharma PLC
Balance Sheet Decomposition is not available for
Evgen Pharma PLC
Evgen Pharma PLC
Balance Sheet
Evgen Pharma PLC
Evgen Pharma PLC
Currency: GBP
| Mar-2014 | Mar-2015 | Mar-2016 | Mar-2017 | Mar-2018 | Mar-2019 | Mar-2020 | Mar-2021 | Mar-2022 | Mar-2023 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Assets | |||||||||||
| Cash & Cash Equivalents |
0
|
0
|
5
|
4
|
4
|
2
|
4
|
6
|
5
|
5
|
|
| Cash |
0
|
0
|
0
|
0
|
0
|
2
|
4
|
6
|
5
|
5
|
|
| Cash Equivalents |
0
|
0
|
5
|
4
|
4
|
0
|
0
|
0
|
0
|
0
|
|
| Short-Term Investments |
0
|
0
|
2
|
0
|
0
|
0
|
0
|
6
|
5
|
0
|
|
| Total Receivables |
0
|
0
|
0
|
1
|
1
|
1
|
1
|
1
|
0
|
1
|
|
| Accounts Receivables |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Other Receivables |
0
|
0
|
0
|
1
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Other Current Assets |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Total Current Assets |
1
|
0
|
7
|
5
|
4
|
3
|
5
|
12
|
10
|
6
|
|
| PP&E Net |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| PP&E Gross |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Accumulated Depreciation |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Intangible Assets |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Total Assets |
1
N/A
|
0
-37%
|
7
+1 956%
|
5
-36%
|
4
-10%
|
3
-35%
|
5
+76%
|
12
+156%
|
10
-22%
|
6
-36%
|
|
| Liabilities | |||||||||||
| Accounts Payable |
0
|
0
|
0
|
1
|
0
|
1
|
1
|
0
|
0
|
0
|
|
| Accrued Liabilities |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Short-Term Debt |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Current Portion of Long-Term Debt |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Other Current Liabilities |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Total Current Liabilities |
0
|
0
|
0
|
1
|
0
|
1
|
1
|
1
|
0
|
1
|
|
| Long-Term Debt |
0
|
1
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Other Liabilities |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Total Liabilities |
0
N/A
|
2
+295%
|
0
-80%
|
1
+64%
|
0
-24%
|
1
+77%
|
1
-5%
|
1
-7%
|
0
-32%
|
1
+103%
|
|
| Equity | |||||||||||
| Common Stock |
1
|
2
|
0
|
0
|
0
|
0
|
0
|
1
|
1
|
1
|
|
| Retained Earnings |
1
|
3
|
4
|
6
|
9
|
11
|
14
|
17
|
19
|
23
|
|
| Additional Paid In Capital |
0
|
0
|
10
|
10
|
13
|
13
|
18
|
28
|
28
|
28
|
|
| Total Equity |
0
N/A
|
1
N/A
|
7
N/A
|
4
-40%
|
4
-8%
|
2
-46%
|
4
+103%
|
12
+181%
|
9
-22%
|
5
-42%
|
|
| Total Liabilities & Equity |
1
N/A
|
0
-37%
|
7
+1 956%
|
5
-36%
|
4
-10%
|
3
-35%
|
5
+76%
|
12
+156%
|
10
-22%
|
6
-36%
|
|
| Shares Outstanding | |||||||||||
| Common Shares Outstanding |
73
|
73
|
74
|
74
|
95
|
100
|
135
|
275
|
275
|
275
|
|
Switch to:
Switch to:
See Also
Discover More
